One way the Asthma and Allergy Foundation of America (AAFA) works on behalf of the more than 60 million people in the U.S. who have asthma and allergies is through research.
We work with doctors, researchers, patients, caregivers, public health, and government agencies to conduct and support research that is important to people affected by asthma and allergies.
As a person with asthma or allergies or a caregiver, you can get involved in research in different ways. You can have a major impact on asthma and allergy research. Here are some of the ways you can help improve treatments, education, and awareness of asthma and allergies right now:
Surveys
Share Your Thoughts on Quick-Relief Inhalers
If you or a loved one have asthma and use a quick-relief (or rescue) inhaler, take this survey about your experiences. The results will help make sure new products line up with your needs and preferences.
You must be 18 years or older and live in the United States to take the survey. At the end of the survey, you can enter for a chance to get one of five $100 gift cards.
Sponsored by Vitapul
Share Your Experiences Living with Nasal Polyps
AAFA is conducting research to learn more about the experiences of people living with nasal polyps. Your insights will help us guide educational content and programmatic resources around nasal polyps. For less than 15 minutes of your time, you can enter for a chance to get one of 10 $100 gift cards.
Supported by Sanofi and Regeneron
Interviews and Focus Groups
Notice to Adolescents and Parents or Adults with CSU
Evidera, a scientific research company, is working with Global Perspectives, a recruitment company to learn about patient perspectives in chronic spontaneous urticaria (CSU).
You are being asked to participate in a 90-minute web-based telephone interview using Microsoft Teams to better understand experiences of people living with CSU as well as your thoughts about a questionnaire used to collect data from individuals with CSU. The study does not involve treatments; we are only interested in opinions.
As compensation for your time, you will receive $150 USD if you are eligible and complete the 90-minute web-based telephone interview using Microsoft Teams.
If you are interested in more information about this study, do not hesitate to contact Anne Skalicky on tollfree number: +1 877 390-3525 or Anne.Skalicky@evidera.com.
Share Your Experiences Living with Severe Asthma
A student researcher from Southern Illinois University is looking to interview people with severe asthma. Interviews will ask about your experiences getting diagnosed and living with asthma, and perceptions of how asthma is shown in the media. Interviews should last less than 30 minutes and can be conducted from the comfort of your own home. For more information, please contact the researcher.
Latest Asthma and Allergy Research News
- NIH Study Links Specific Outdoor Air Pollutants to Asthma Attacks in Urban Children
The NIH study found that moderate levels of two outdoor air pollutants – ozone, and fine particulate matter – are linked to asthma attacks among children in low-income urban areas. The study also found links between exposure to air pollution and changes in children’s airways during asthma attacks. This is one of the first studies to link air pollution with changes in the airways and show how important it is to reduce air pollution for public health. - Study Finds That About 13% Of Childhood Asthma Cases in the U.S. Can Be Linked to Gas Stove Use
In a December study published in the “International Journal of Environmental Research and Public Health,” researchers found that indoor gas stove use is linked to a higher risk of asthma in children. The researchers estimate that 13% of current childhood asthma cases can be linked to gas stove use. Though more research is needed, the results of the study highlight the importance of indoor air quality and the steps you can take to reduce asthma and allergy triggers in the home. - FDA Approves AIRSPURA® for As-Needed Use to Reduce the Risk of Asthma Attacks
AIRSPURA® is an as-needed quick-relief inhaler now approved for people with asthma aged 18 and older. It combines albuterol and budesonide. The Food and Drug Administration’s (FDA) approval of AIRSPURA® is based on the results from two clinical trials called MANDALA and DENALI. The results showed that AIRSPURA® can lower the risk of a severe asthma attack in people with moderate-to-severe asthma and can improve lung function in people with mild-to-moderate asthma. - FDA Approves ODACTRA® Tablet for Sublingual Use as Immunotherapy for Adolescents
ODACTRA® is a tablet that can help treat allergy symptoms to house dust mites. It is a type of treatment called sublingual immunotherapy (SLIT), where a tablet is placed under the tongue and then swallowed when dissolved. The tablets will increase your tolerance to certain allergens and reduce your symptoms over time. ODACTRA® was first approved by the FDA in 2017 for people ages 18 to 65. It is now approved for people ages 12 to 65.
- New CDC Data on Allergic Conditions
The Centers for Disease for Control and Prevention (CDC) recently released two data briefs on diagnosed allergic conditions in adults and children. Data briefs are topic-specific documents focusing on public health issues.
The data briefs show that in 2021 nearly 1 in 3 adults and more than 1 in 4 children in the U.S. had seasonal allergies, eczema, or food allergies. Almost 6% of U.S. adults and children have a food allergy.
These data briefs also look at the differences in allergy trends between sex, age, race, and Hispanic ethnicity. They showed that non-Hispanic Black adults and children are more likely to have food allergy than non-Hispanic white or Hispanic adults and children.
Coming Soon!
Keep an eye out for our upcoming 2023 Allergy Capitals™ report in March.
It is important to stay up to date on news about asthma and allergies. By joining our community and following our blog, you will receive news about research and treatments. Our community also provides an opportunity to connect with other people who manage these conditions for support.
Comments (0)